tbuckley/cabot-search huggingface dataset:
Relative risks of adverse events among older adults receiving opioids versus NSAIDs after hospital discharge: A nationwide cohort study
Authors: Shoshana J. Herzig, Timothy S. Anderson, Yoojin Jung, Long Ngo, Dae H. Kim, Ellen P. McCarthy
Journal: PLoS Medicine (2021)

Background Although analgesics are initiated on hospital discharge in millions of adults each year, studies quantifying the risks of opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) among older adults during this transition are limited. We sought to determine the incidence and risk of post-discharge adverse events among older adults with an opioid claim in the week after hospital discharge, compared to those with NSAID claims only. Methods and findings We performed a retrospective cohort study using a national sample of Medicare beneficiaries age 65 and older, hospitalized in United States hospitals in 2016. We excluded beneficiaries admitted from or discharged to a facility. We derived a propensity score that included over 100 factors potentially related to the choice of analgesic, including demographics, diagnoses, surgeries, and medication coadministrations. Using 3:1 propensity matching, beneficiaries with an opioid claim in the week after hospital discharge (with or without NSAID claims) were matched to beneficiaries with an NSAID claim only. Primary outcomes included death, healthcare utilization (emergency department [ED] visits and rehospitalization), and a composite of known adverse effects of opioids or NSAIDs (fall/fracture, delirium, nausea/vomiting, complications of slowed colonic motility, acute renal failure, and gastritis/duodenitis) within 30 days of discharge. After propensity matching, there were 13,385 beneficiaries in the opioid cohort and 4,677 in the NSAID cohort (mean age: 74 years, 57% female). Beneficiaries receiving opioids had a higher incidence of death (1.8% versus 1.1%; relative risk [RR] 1.7 [1.3 to 2.3], p &lt; 0.001, number needed to harm [NNH] 125), healthcare utilization (19.0% versus 17.4%; RR 1.1 [1.02 to 1.2], p = 0.02, NNH 59), and any potential adverse effect (25.2% versus 21.3%; RR 1.2 [1.1 to 1.3], p &lt; 0.001, NNH 26), compared to those with an NSAID claim only. Specifically, they had higher relative risk of fall/fracture (4.5% versus 3.4%; RR 1.3 [1.1 to 1.6], p = 0.002), nausea/vomiting (9.2% versus 7.3%; RR 1.3 [1.1 to 1.4], p &lt; 0.001), and slowed colonic motility (8.0% versus 6.2%; RR 1.3 [1.1 to 1.4], p &lt; 0.001). Risks of delirium, acute renal failure, and gastritis/duodenitis did not differ between groups. The main limitation of our study is the observational nature of the data and possibility of residual confounding. Conclusions Older adults filling an opioid prescription in the week after hospital discharge were at higher risk for mortality and other post-discharge adverse outcomes compared to those filling an NSAID prescription only.
1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK
Authors: S-E. Al-Batran, S. Lorenzen, N. Homann, P.C. Thuss-Patience, M. Schenk, U. Lindig, A. Kretzschmar, V. Heuer, E. Goekkurt, G.M. Haag, J. Riera Knorrenschild, C. Bolling, R.D. Hofheinz, A.R. Siebenhuener, N. Irahara, C. Kopp, L. Waberer, C. Pauligk, T.O. Götze, T. Gaiser
Journal: Annals of Oncology (2021)
Looking Over the Drape—Anesthesiologists’ Volume and Surgical Outcomes
Authors: Andrea Amabile, Panos N. Vardas, Carlo Maria Rosati
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
1648P Phased avelumab combined with chemotherapy as first-line treatment in extensive stage small cell lung cancer (PAVE): A phase II Hellenic Cooperative Oncology Group study
Authors: H. Linardou, G-A. Koliou, E. Samantas, D.I. Lampropoulou, N. Spathas, E. Fountzilas, A.N. Christopoulou, A. Psyrri, E. Kosmas, I. Vamvakaris, A. Koumarianou, D. Bafaloukos, G. Fountzilas, G. Mountzios
Journal: Annals of Oncology (2021)
Social bonding and credible signaling hypotheses largely disregard the gap between animal vocalizations and human music
Authors: Marcel Zentner
Journal: Behavioral and Brain Sciences (2021)

Abstract Mehr et al. propose a theory of the evolution music that can potentially account for most animal vocalizations as precursors to human music. Therein lies its appeal but also its Achilles' heel, for the wider the range of animal vocalizations treated as premusical expressions, the wider the gap to human music. Here, I offer a few critical observations and constructive suggestions that I hope will help the authors strengthen their case.
1787P RAS precision medicine trans-Atlantic partnership: Multi-centre analysis of RAS and NF1 co-mutations in advanced NSCLC
Authors: H. Adderley, M. Aldea, J. Aredo, M. Carter, M. Church, A. Ghaus, D. Planchard, D. Vasseur, C. Massard, M.G. Krebs, N. Steele, F.H. Blackhall, H. Wakelee, B. Besse, C. Lindsay
Journal: Annals of Oncology (2021)
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study
Authors: Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Hitendra Patel, Mina Nikanjam, Paul T. Fanta, Michael E. Hahn, Pradip De, Casey Williams, Jessica Guido, Benjamin M. Solomon, Rana R. McKay, Amy Krie, Sarah G. Boles, Jeffrey S. Ross, J. Jack Lee, Brian Leyland-Jones, Scott M. Lippman, Razelle Kurzrock
Journal: Genome Medicine (2021)

Malignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naïve, advanced cancers would be feasible and efficacious. Patients with newly diagnosed unresectable/metastatic, poor-prognosis cancers were enrolled in a cross-institutional prospective study.A total of 145 patients were included in the study. Genomic profiling (tissue and/or circulating tumor DNA) was performed in all patients, and PD-L1 immunohistochemistry, tumor mutational burden, and microsatellite status assessment were performed in a subset of patients. We evaluated safety and outcomes: disease-control rate (stable disease for ≥ 6 months or partial or complete response), progression-free survival (PFS), and overall survival (OS).Seventy-six of 145 patients (52%) were treated, most commonly for non-colorectal gastrointestinal cancers, carcinomas of unknown primary, and hepatobiliary malignancies (53% women; median age, 63 years). The median number of deleterious genomic alterations per patient was 5 (range, 0-15). Fifty-four treated patients (71%) received ≥ 1 molecularly matched therapy, demonstrating the feasibility of administering molecularly matched therapy. The Matching Score, which reflects the percentage of targeted alterations, correlated linearly with progression-free survival (R2 = 0.92; P = 0.01), and high (≥ 60%) Matching Score was an independent predictor of improved disease control rate [OR 3.31 (95% CI 1.01-10.83), P = 0.048], PFS [HR 0.55 (0.28-1.07), P = 0.08], and OS [HR 0.42 (0.21-0.85), P = 0.02]. Serious adverse event rates were similar in the unmatched and matched groups.Personalized combination therapies targeting a majority of a patient's molecular alterations have antitumor activity as first-line treatment. These findings underscore the feasibility and importance of using tailored N-of-1 combination therapies early in the course of lethal malignancies.I-PREDICT ( NCT02534675 ) was registered on August 25, 2015.
1102P The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses
Authors: P.B. Ruszniewski, M.E. Caplin, P.L. Kunz, L. Bodei, A.E. Hendifar, E. Mittra, E.M. Wolin, J.C. Yao, M.E. Pavel, E. Grande, E. Van Cutsem, E. Seregni, H. Duarte, A. Demange, S. Mutevelic, E.P. Krenning, J.R. Strosberg
Journal: Annals of Oncology (2021)
Hard to Swallow
Authors: Michael J. Litt, Rebecca Gaffney, Anand Vaidya, Mary W. Montgomery
Journal: New England Journal of Medicine (2021)

A 20-year-old woman is admitted to the hospital after presenting to the emergency department with pain in her throat and the left side of her neck, fever, foul-smelling breath, and an inability to clear secretions. She reports three recent bouts of nonbloody, nonbilious emesis, a deepening of her voice, and severe pain when she tries to open her mouth. The throat pain as well as malaise and occasional chills developed 10 days before presentation. . . .
518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors
Authors: M. Sharma, B. Bashir, E. Hamilton, D. Juric, K. Papadopoulos, D. Richardson, G. Shapiro, G. Hodgson, N. Ke, A. D'Ippolito, S. Henry, L. Zhu, M. Rosario, H. Jolin, D. Roth, V. Klimek, C. Madigan, M. Kelly
Journal: Annals of Oncology (2021)
Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
Authors: Huicheng Liu, Lili Bai, Liu Huang, Na Ning, Lin Li, Yijia Li, Xuejiao Dong, Qiuyang Du, Minghui Xia, Yufei Chen, Likun Zhao, Yanhu Li, Qingwu Meng, Jing Wang, Yaqi Duan, Jie Ming, Andy Qingan Yuan, Xiang-Ping Yang
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Triple negative breast cancer (TNBC) is a subtype of breast cancers with poor prognosis and targeted drug therapies are limited. To develop novel and efficacious therapies for TNBC, we developed a bispecific antibody F7AK3 that recognizes both trophoblast cell surface antigen 2 (TROP2) and CD3 and evaluated its antitumor activities both in vitro and in vivo. Methods The binding affinities of F7AK3 to the two targets, TROP2 and CD3, were evaluated by surface plasmon resonance. Binding of F7AK3 to TNBC cells and T cells were evaluated by flow cytometry. Immunofluorescent staining was performed to demonstrate the interactions between T cells with TNBC cells. The cytotoxicity of T cells against TNBC cell lines and primary tumor cells mediated by F7AK3 were determined in vitro. In vivo antitumor activity of F7AK3 was investigated in a xenograft TNBC tumor model, using immunodeficient mice that were reconstituted with human peripheral blood mononuclear cells. Results We demonstrated that F7AK3 binds specifically to human TROP2 and CD3 antigens, as well as TNBC cell lines and primary tumor cells. Human T cells can only be activated by F7AK3 in the presence of target tumor cells. F7AK3 recruits T cells to TROP2 + tumor cells in vitro and into tumor tissues in vivo. Antitumor growth activity of F7AK3 is observed in a xenograft TNBC tumor model. Conclusion This study showed the antitumor potential of an anti-TROP2xCD3 bispecific antibody F7AK3 to TNBC tumor cells both in vitro and in vivo. These data demonstrate that F7AK3 has the potential to treat TNBC patients, which warrants further preclinical and clinical evaluation of the F7AK3 in advanced or metastatic TNBC patients.
Comparative pathology of the nasal mucosa in laboratory animals exposed to inhaled irritants.
Authors: J R Harkema
Journal: Environmental Health Perspectives (1990)

The nasal cavity is susceptible to chemically induced injury as a result of exposure to inhaled irritants. Some responses of the nasal mucosa to inhaled toxicants are species specific. These species-related differences in response may be due to variations in structural, physiologic, and biochemical factors, such as gross nasal cavity structure, distribution of luminal epithelial cell populations along the nasal airway, intranasal airflow patterns, nasal mucociliary apparatus, and nasal xenobiotic metabolism among animal species. This paper reviews the comparative anatomy and irritant-induced pathology of the nasal cavity in laboratory animals. The toxicologist, pathologist, and environmental risk assessor must have a good working knowledge of the similarities and differences in normal nasal structure and response to injury among species before they can select animal models for nasal toxicity studies, recognize toxicant-induced lesions in the nasal airway, and extrapolate experimental results to estimate the possible effects of an inhaled toxicant on the human nasal airway.
Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer’s disease
Authors: Neus Barranco, Virginia Plá, Daniel Alcolea, Irene Sánchez-Domínguez, Reiner Fischer-Colbrie, Isidro Ferrer, Alberto Lleó, Fernando Aguado
Journal: Translational Neurodegeneration (2021)

Abstract Background New fluid biomarkers for Alzheimer's disease (AD) that reveal synaptic and neural network dysfunctions are needed for clinical practice and therapeutic trial design. Dense core vesicle (DCV) cargos are promising cerebrospinal fluid (CSF) indicators of synaptic failure in AD patients. However, their value as biomarkers has not yet been determined. Methods Immunoassays were performed to analyze the secretory proteins prohormone convertases PC1/3 and PC2, carboxypeptidase E (CPE), secretogranins SgIII and SgII, and Cystatin C in the cerebral cortex ( n = 45, provided by Bellvitge University Hospital) and CSF samples ( n = 66, provided by The Sant Pau Initiative on Neurodegeneration cohort) from AD patients ( n = 56) and age-matched controls ( n = 55). Results In AD tissues, most DCV proteins were aberrantly accumulated in dystrophic neurites and activated astrocytes, whereas PC1/3, PC2 and CPE were also specifically accumulated in hippocampal granulovacuolar degeneration bodies. AD individuals displayed an overall decline of secretory proteins in the CSF. Interestingly, in AD patients, the CSF levels of prohormone convertases strongly correlated inversely with those of neurodegeneration markers and directly with cognitive impairment status. Conclusions These results demonstrate marked alterations of neuronal-specific prohormone convertases in CSF and cortical tissues of AD patients. The neuronal DCV cargos are biomarker candidates for synaptic dysfunction and neurodegeneration in AD.
775P Tremelimumab (T) + durvalumab (D) combined with metronomic oral vinorelbine (MOV): Results of the recurrent cervical cancer (RCC) cohort of the MOVIE study
Authors: J-S. Frenel, A. Hervieu, E. Borcoman, E. Coquan, J. Guigay, T. De La Motte Rouge, P. Lavaud, C. Cropet, F. Legrand, A. Gonçalves
Journal: Annals of Oncology (2021)
Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis
Authors: Andrea Angeletti, Maurizio Bruschi, Gabriella Moroni, Renato Alberto Sinico, Franco Franceschini, Micaela Fredi, Augusto Vaglio, Lorenzo Cavagna, Andrea Petretto, Federico Pratesi, Paola Migliorini, Francesco Locatelli, Giulia Pazzola, Giampaola Pesce, Marcello Bagnasco, Angelo Manfredi, Giuseppe A. Ramirez, Pasquale Esposito, Giuseppe Murdaca, Simone Negrini, Leda Cipriani, Barbara Trezzi, Giacomo Emmi, Ilaria Cavazzana, Valentina Binda, Matteo d’Alessandro, Paride Fenaroli, Isabella Pisani, Giacomo Garibotto, Carlomaurizio Montecucco, Domenico Santoro, Francesco Scolari, Stefano Volpi, Marta Mosca, Angela Tincani, Giovanni Candiano, Marco Prunotto, Enrico Verrina, Angelo Ravelli, Gian Marco Ghiggeri
Journal: Journal of the American Society of Nephrology (2021)

Clinical Trial registry name and registration number: Zeus study, NCT02403115
1576P COVID-CANCER HUIL - Registry of oncological patients with diagnosis of COVID-19 at Hospital Universitario Infanta Leonor in Madrid (Spain): One year of pandemic
Authors: J. Rogado, B. Obispo, M. Pérez-Pérez, A. Martín-Marino, J.L. García-López, A. Lopez-Alfonso, C. Pangua, G. Serrano-Montero, M.A. Lara
Journal: Annals of Oncology (2021)
Multicomponent Strategies to Prevent SARS-CoV-2 Transmission — Nine Overnight Youth Summer Camps, United States, June–August 2021
Authors: Kim Van Naarden Braun, Mark Drexler, Ranna A. Rozenfeld, Eytan Deener-Agus, Rebecca Greenstein, Michael Agus, Mark Joffe, Andrea Kasowitz, Philip Levy, Cliff Nerwen
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Most U.S. overnight youth camps did not operate during the summer of 2020 because of the COVID-19 pandemic* (1). Several that did operate demonstrated that multiple prevention strategies, including pre- and postarrival testing for SARS-CoV-2, the virus that causes COVID-19, masking, and physical distancing helped prevent the introduction and spread of COVID-19; in contrast, camps that relaxed prevention strategies, such as requiring a single prearrival test without subsequent testing, experienced outbreaks (2-4). The availability of COVID-19 vaccines for persons aged ≥12 years enabled implementation of an additional prevention strategy that was not available in summer 2020. This study assessed the number of COVID-19 cases and potential secondary spread among 7,173 staff members and campers from 50 states, 13 countries, and U.S. military overseas bases at nine independently operated U.S. summer youth camps affiliated with the same organization. The camps implemented multiple prevention strategies including vaccination, testing, podding (cohorting), masking, physical distancing, and hand hygiene during June-August 2021. Vaccination coverage was 93% among eligible persons aged ≥12 years.† All staff members (1,955) and campers (5,218) received site-specific, protocol-defined screening testing, which included prearrival testing and screening tests during the camp session (38,059 tests). Screening testing identified six confirmed COVID-19 cases (one in a staff member and five in campers) by reverse transcription-polymerase chain reaction (RT-PCR) testing (screening test positivity rate = 0.02%). Three additional cases (in two staff members and one camper) were identified based on symptoms and were confirmed by RT-PCR testing. Testing for SARS-CoV-2, isolation, and quarantine in a population with high vaccination coverage resulted in no known secondary transmission of SARS-CoV-2 identified during camp. Implementation of multicomponent strategies is critical for prevention of COVID-19 outbreaks in congregate settings, including overnight youth camps.
1624P Impact of the COVID-19 pandemic in the cancer fast-track programme
Authors: M.T.M. Martinez, S. Simón, J. Montón-Bueno, S. Moragón, B. Ortega Morillo, S. Roselló, J. Navarro, A. Sanmartin, A. Julve, M. Flores, E. Buch, A. Peña, J. Franco, J. Martínez-Jabaloyas, J. Marco, M.J. Forner, A. Cano, B. Bermejo, A. Cervantes, I. Chirivella
Journal: Annals of Oncology (2021)
617P Genomic profiling of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Nationwide Cancer Genome Screening Project
Authors: T. Kato, N. Matsubara, T. Fujisawa, M. Shiota, M. Eto, T. Osawa, T. Abe, N. Shinohara, Y. Yasumizu, N. Tanaka, M. Oya, K. Nishimoto, S. Horasawa, N. Kuramoto, Y. Nakamura, H. Taniguchi, T. Yoshino, N. Nonomura
Journal: Annals of Oncology (2021)
Welcoming c-MAF to the macrophage transcription factor VAM-ily
Authors: Pieter A. Louwe, Charlotte L. Scott
Journal: Science Immunology (2021)

The transcription factor c-MAF regulates perivascular macrophage phenotypes across tissues, including white adipose tissue, where its loss from murine vasculature–associated macrophages leads to increased vascularization and protection from metabolic syndrome (see the related Research Article by Moura Silva et al . ).
Cognate recognition of microbial antigens defines constricted CD4+ T cell receptor repertoires in the inflamed colon
Authors: Moritz Muschaweck, Lydia Kopplin, Fabio Ticconi, Angela Schippers, Aida Iljazovic, Eric J.C. Gálvez, Ali T. Abdallah, Norbert Wagner, Ivan G. Costa, Till Strowig, Oliver Pabst
Journal: Immunity (2021)
521P Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors
Authors: J. Tabernero, P. Bedard, Y-J. Bang, M. Vieito, M-H. Ryu, N. Fagniez, S. Yoruk, L. Charbonnier, C. Soufflet, N. Masson, A. Gazzah
Journal: Annals of Oncology (2021)
Injectable Mussel‐Inspired highly adhesive hydrogel with exosomes for endogenous cell recruitment and cartilage defect regeneration
Authors: Fang-Xue Zhang, Peng Liu, Wang Ding, Qing-Bing Meng, Di-Han Su, Qi-Chen Zhang, Rui-Xian Lian, Bao-Qing Yu, Ming-Dong Zhao, Jian Dong, Yu-Lin Li, Li-Bo Jiang
Journal: Biomaterials (2021)
Closure of a duodenal cutaneous fistula with endoscopic negative pressure therapy using a thin open-pore film drain – an easy tool and simple method
Authors: Gunnar Loske, Johannes Müller, Anja Röske, Dalia Majert, Wolfgang Schulze, Christian Theodor Mueller
Journal: Endoscopy (2021)

A 57-year-old patient underwent emergency laparotomy for an acute abdomen with free intra-abdominal air caused by a perforated distal gastric ulcer. Surgical closure was performed by suture. Histological adenocarcinoma was found Therefore, revision laparotomy with distal gastric resection and Roux-en-y reconstruction was done 3 days later. At 6 days postoperatively, a discharge of biliary secretions via target drainage for duodenal stump insufficiency was seen. Surgical closure was tried in another revision laparotomy. But again biliary secretion occurred proving the persistent duodenal leakage.
139P HER2+/HR+ breast cancer patients at high risk of relapse derive benefit from extended adjuvant treatment with neratinib: An exploratory analysis from ExteNET study
Authors: F. Cognetti, S. Di Cosimo, P. Bruzzi, F. Caprari, E. Dapretto, J-B. Trouiller, R. Valenti, P. Pronzato
Journal: Annals of Oncology (2021)